Advisers to the FDA voted unanimously to recommend the approval of Eli Lilly’s drug for early Alzheimer’s disease, Donanemab, citing its ability to slow cognitive decline outweighing safety risks. This outcome is favorable for Lilly, making FDA approval likely for a broad population of patients with mild cognitive impairment due to Alzheimer’s. Neurologist Kathleen Poston stated that the benefits outweigh the risks with proper monitoring. A decision is expected later this year. This news is exclusive to STAT+ subscribers, providing in-depth coverage and analysis of the biotech sector. The drug approval is seen as a significant development in the treatment of Alzheimer’s disease.
Source link
Lilly’s Alzheimer’s drug donanemab backed by FDA advisers
